Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Waldenström's macroglobulinemia is a rare disease whose pathophysiology remains at present poorly understood, although a recurrent mutation (L265P MYD88) has recently been described. Unlike other lymphoproliferative disorders, there is a defect in isotype switching, mechanism involving AID and NHEJ complex. Using a two-dimensional electrophoresis technology, our group showed that MW had a specific proteomic profile, and one of the differentially expressed proteins is Ku70 (encoded by XRCC6 belonging to NHEJ complex) .

The investigators purpose to explore the mechanisms of underexpression of Ku70/XRCC6 (genetic or epigenetic modification) in comparison with other lymphoid malignancies and normal B cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

NCT04893564

Waldenstrom's Disease Waldenstrom Macroglobulinemia

RECRUITING NA

Detection of Recurrent Mutations in Waldenström's Disease

NCT03952052

Waldenstrom's Disease

COMPLETED NA

Transformed Waldenström Macroglobulineamia

NCT03611959

Transformed Waldenström Macroglobulineamia

COMPLETED

Immunoglobulin Gene Rearrangement and Repair in Healthy Donors

NCT04889573

Healthy Volunteers

COMPLETED NA

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

NCT01177527

Multiple Myeloma Waldenstrom's Macroglobulinemia Smoldering Multiple Myeloma +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Waldenström Macroglobulinemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Waldenström macroglobulinemia

Patients with diagnosis of Waldenström macroglobulinemia

Group Type EXPERIMENTAL

Blood or bone marrow samples

Intervention Type BIOLOGICAL

Others B-cell malignancies

Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma

Group Type EXPERIMENTAL

Blood or bone marrow samples

Intervention Type BIOLOGICAL

Healthy subjects

Control healthy subjects without B-cell malignancy

Group Type OTHER

Blood or bone marrow samples

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood or bone marrow samples

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years, affiliated to the social regimen
* Written consent collected

MW group :

* Patient with a diagnosis of MW according to WHO criteria (based on the results of serum protein electrophoresis, bone marrow analysis with immunophenotyping, cytogenetic analysis and mutation L265P MyD88)

Other SLP :

* Patient with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma

Healthy volunteers :

* volunteers without blood disorders

Exclusion Criteria

* Women of childbearing age who do not have an effective means of contraception
* Pregnant or nursing
* Demonstration of a kappa or lambda monotype on B lymphocytes
* healthy volunteer with B-cell malignancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes